Kidney Transplant in India FAQ 2026: Top Questions Answered by India's Leading Specialists

Living donor kidney transplant: USD 12,000-22,000 (vs USD 80,000-200,000 in the USA, USD 50,000-100,000 in the UAE, USD 25,000-50,000 in the UK). Deceased donor transplant: USD 11,000-20,000. ABO-incompatible: USD 15,000-25,000. Combined kidney-pancreas: USD 18,000-28,000. Includes pre-op workup, surgeon, anesthesia, ICU, ward, immunosuppressants (1 year), and 1-year follow-up.

1-year graft survival in India: 95-98%. 5-year: 85-90%. 10-year: 70-75%. Patient survival 1-year: 97-99%. Delayed graft function (DGF) < 5%. Acute rejection: 10-15% in first 6 months, steroid-responsive in 90%+. Top Indian centers (Medanta, Apollo, Fortis, Max, Manipal) match UNOS registry outcomes.

Donor eligibility: 18-65 years, no hypertension/diabetes/kidney disease, compatible blood type, no chronic infections, normal kidney function (eGFR > 90), no proteinuria. Workup includes CT angiography, renogram (each kidney's function), psych clearance. Donor lifetime risks: 0.03% mortality, <1% major complication, normal life expectancy after donation.

ABOi transplant is kidney transplant across blood-type barriers, made possible by pre-conditioning (plasmapheresis + rituximab to remove blood-type antibodies). Outcomes match ABO-compatible transplants. Cost USD 15,000-25,000 in India. Top centers (Medanta, Apollo) have done 100+ ABOi with 95%+ 1-year graft survival.

Standard plan: 2 days pre-op workup, 7-10 days hospital, 7-10 days monitoring. Total: 16-22 days. Donor stays 5-7 days. Patients should stay near transplant center 4-6 weeks post-op to monitor for rejection, infection, surgical complications. Flight clearance at 4-6 weeks.

Triple regimen: tacrolimus + mycophenolate + prednisone (tapered off at 6-12 months). Some patients transition to mTOR inhibitor (sirolimus/everolimus) or belatacept. Cost USD 150-400/month. Lifelong adherence is critical; non-compliance is the leading cause of graft loss.

Early (first 30 days): rejection (10-15%), infection (10-20%), bleeding (1-3%), DVT (1%), wound complications (1-5%). Late: chronic rejection (5-10%), recurrent disease (FSGS, IgA), malignancy (2-4% increased), cardiovascular disease. Modern protocols reduce early rejection below 10%.

Yes — GCC donors are accepted; combined recipient-donor visas are arranged. Donor workup is expedited (5-7 days), and both are operated within 24 hours. Spouse, parents, children, siblings are typically considered first; unrelated donors require documentation proving emotional relationship (Transplantation of Human Organs Act 2014).

For incompatible donor-recipient pairs, India's top centers participate in paired exchange: donor A gives to recipient B, donor B gives to recipient A. Cost similar to standard transplant (USD 12,000-22,000). Outcomes are excellent. Some centers run 3-way and 4-way swaps, increasing matched-pair rates.

90%+ of recipients do not need dialysis after a successful transplant. Delayed graft function (DGF, requiring temporary dialysis in the first 1-2 weeks) occurs in 5-10% of deceased donor and 1-3% of living donor transplants. Once recovered, the transplanted kidney takes over; most recipients feel markedly better within days.

Yes — second (and third) kidney transplants are performed in India. Indications: primary non-function, chronic rejection, recurrent disease. Cost slightly higher (USD 18,000-28,000). Top centers (Medanta, Apollo) report 90%+ graft survival at 1 year for second transplants.

Standard: 4-6 weeks post-transplant. Clearance criteria: stable creatinine, no rejection episodes, no active infection, stable immunosuppression. Most patients fly home with a medical escort on commercial flights; some hospitals offer commercial stretcher or air ambulance services.

Tele-consults at 1, 3, 6, 12 months then annually. Local lab monitoring (creatinine, tacrolimus trough, CBC, LFT) by patient with results uploaded to hospital portal. Prescription refills arranged for 6-12 months. Annual review visit to India recommended (often combined with tourism).

Indications: combined liver failure + ESRD, polycystic liver and kidney disease, primary hyperoxaluria type 1. Cost USD 18,000-28,000 in India. Outcomes: 1-year survival 85-90%. Performed at major transplant centers (Medanta, Apollo, Global).

Induction therapy: anti-thymocyte globulin (ATG) or basiliximab at transplant. Maintenance: tacrolimus + mycophenolate + prednisone taper. Acute rejection (10-15%): treated with high-dose methylprednisolone (90%+ success). Severe or steroid-resistant: anti-thymocyte globulin, rituximab.

Yes — long-term studies show donors live normal lifespans with one kidney. Kidney function recovers to 70-80% of pre-donation within 1-2 weeks. Long-term risks: small increase in hypertension (5-10%), negligible increase in ESRD risk (matched to general population). Donors receive annual check-ups at the transplant center.

Wait time for deceased donor transplant varies (1-3 years for blood group B; 3-6 months for O). NOTTO maintains a national waiting list. Living donor transplant is preferred at Indian centers because of shorter wait, better outcomes, and cost.